Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma

Clinical Cancer Research

Volumn 7, Issue 12, 2001, Pages 3994-3999

  Fiorentino, Michelangelo ^a   Altimari, Annalisa ^a   D’Errico, Annalisa ^a   Gabusi, Elena ^a   Chieco, Pasquale ^a   Grigioni, Walter Franco ^a   Masetti, Michele ^b  

^a Istituto Oncologico Addarii   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P27;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR LOCALIZATION;

CELL DIVISION; CHOLANGIOCARCINOMA; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 0035671871     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Kip1, a cyclin dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
2. Cancer cell cycles
3. 1 restriction point
4. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
5. Kip1 mutation found in breast cancer
6. Kip1 in human malignancies
7. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas
8. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
9. Kip1 protein: Prognostic implication in primary breast cancer
10. Increased proteasome-dependent degradation of the cyclin-depend kinase inhibitor p27 in aggressive colorectal carcinoma
11. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastasis
12. Kip1 in multistage colorectal carcinogenesis
13. p27 expression and gastric carcinoma
14. Kip1 gene expression in benign prostatic hyperplasia and prostatic carcinoma
15. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma
16. Loss or altered subcellular localization of p27 in Barrett’s associated adenocarcinoma
17. Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer
18. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer
19. 1-S modulators in hepatocellular carcinoma: P27 independently predicts the recurrence
20. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma
21. Kip1 expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma
22. Kip1 expression in normal epithelia, precancerous lesions and carcinomas of the gall-bladder: Association with cancer progression and prognosis
23. Tumors of the liver and intrahepatic bile ducts
24. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis: An unusual tumor with distinctive clinical and pathological features
25. Biliary tract cancers
26. Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: Relationship with p53 overexpression, Ki67 labeling and clinico-pathological features
27. 1-S modulators in the carcinoma of the extrahepatic bile duct
28. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis
29. Expression of mucin core protein of mammary type in primary liver cancer
30. c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma
31. Regression models and life tables
32. Nonparametric estimation for incomplete observations
33. Prognostic value of cell proliferation (Ki-67 antigen) and nuclear DNA content in clinically resectable, distal bile duct carcinoma
34. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience
35. Surgery for hilar cholangiocarcinoma: An Italian experience
36. Resection of hilar cholangiocarcinoma: A European and United States experience
37. Surgery for hilar cholangiocarcinoma: The Johns Hopkins approach